Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1982 1
1984 1
1985 1
1986 5
1987 2
1988 2
1989 4
1990 3
1991 5
1992 8
1993 4
1994 3
1995 8
1996 3
1998 5
1999 6
2000 6
2001 4
2002 4
2003 4
2004 7
2005 7
2006 6
2007 7
2008 4
2009 16
2010 18
2011 19
2012 12
2013 10
2014 19
2015 12
2016 24
2017 13
2018 13
2019 18
2020 13
2021 13
2022 11
2023 7
2024 9
2025 13
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Results by year

Filters applied: . Clear all
Page 1
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Natale P, Green SC, Ruospo M, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Natale P, et al. Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4. Cochrane Database Syst Rev. 2025. PMID: 40576086 Free PMC article.
BACKGROUND: Phosphate binders lower serum phosphate levels for people with chronic kidney disease (CKD). ...OBJECTIVES: To assess the benefits and harms of phosphate binders for people with CKD and whether phosphat …
BACKGROUND: Phosphate binders lower serum phosphate levels for people with chronic kidney disease (CKD …
Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.
Hu L, Napoletano A, Provenzano M, Garofalo C, Bini C, Comai G, La Manna G. Hu L, et al. Int J Mol Sci. 2022 Oct 13;23(20):12223. doi: 10.3390/ijms232012223. Int J Mol Sci. 2022. PMID: 36293076 Free PMC article. Review.
Chronic kidney disease-mineral bone disorders (CKD-MBD) with biochemical and hormonal alterations are part of the complications associated with the progression of CKD. ...We therefore examine the prognostic association betwe …
Chronic kidney disease-mineral bone disorders (CKD-MBD) with biochemical and hormonal alter …
Lowering Expectations with Niacin Treatment for CKD-MBD.
Drüeke TB, Massy ZA. Drüeke TB, et al. Clin J Am Soc Nephrol. 2018 Jan 6;13(1):6-8. doi: 10.2215/CJN.12021017. Epub 2017 Dec 5. Clin J Am Soc Nephrol. 2018. PMID: 29208625 Free PMC article. No abstract available.
Pediatric CKD-MBD: existing and emerging treatment approaches.
Ayoob RM, Mahan JD. Ayoob RM, et al. Pediatr Nephrol. 2022 Nov;37(11):2599-2614. doi: 10.1007/s00467-021-05265-8. Epub 2022 Jan 17. Pediatr Nephrol. 2022. PMID: 35038008
The effects of bone and mineral metabolism on skeletal formation, as well as vascular and soft tissue calcifications, define chronic kidney disease-metabolic bone disease (CKD-MBD). ...These approaches are associated with improved bone …
The effects of bone and mineral metabolism on skeletal formation, as well as vascular and soft tissue calcifications, define chron …
Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials.
Xu C, Smith ER, Tiong MK, Ruderman I, Toussaint ND. Xu C, et al. J Am Soc Nephrol. 2022 May;33(5):1011-1032. doi: 10.1681/ASN.2021101327. Epub 2022 Mar 1. J Am Soc Nephrol. 2022. PMID: 35232774 Free PMC article.
BACKGROUND: Vascular calcification is associated with cardiovascular morbidity and mortality in people with CKD. Evidence-based interventions that may attenuate its progression in CKD remain uncertain. ...Trials involving magnesium and sodium thiosulfate consistentl …
BACKGROUND: Vascular calcification is associated with cardiovascular morbidity and mortality in people with CKD. Evidence-based inter …
Phosphate, Microbiota and CKD.
Favero C, Carriazo S, Cuarental L, Fernandez-Prado R, Gomá-Garcés E, Perez-Gomez MV, Ortiz A, Fernandez-Fernandez B, Sanchez-Niño MD. Favero C, et al. Nutrients. 2021 Apr 13;13(4):1273. doi: 10.3390/nu13041273. Nutrients. 2021. PMID: 33924419 Free PMC article. Review.
Phosphate is a key uremic toxin associated with adverse outcomes. As chronic kidney disease (CKD) progresses, the kidney capacity to excrete excess dietary phosphate decreases, triggering compensatory endocrine responses that drive CKD …
Phosphate is a key uremic toxin associated with adverse outcomes. As chronic kidney disease (CKD) progresses, th …
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Ruospo M, et al. Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2025 Jun 27;6:CD006023. doi: 10.1002/14651858.CD006023.pub4. PMID: 30132304 Free PMC article. Updated.
BACKGROUND: Phosphate binders are used to reduce positive phosphate balance and to lower serum phosphate levels for people with chronic kidney disease (CKD) with the aim to prevent progression of chronic kidney dis …
BACKGROUND: Phosphate binders are used to reduce positive phosphate balance and to lower serum phosphate levels …
[Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
Iwashita Y, Iwashita Y, Ito T, Shigematsu T. Iwashita Y, et al. Clin Calcium. 2016 Feb;26(2):259-67. Clin Calcium. 2016. PMID: 26813506 Review. Japanese.
In addition,a new concept has been proposed "CKD-MBD". CKD-MBD is composed of a combination of abnormal mineral metabolism, abnormal bone, and extra skeletal calcification with cardiovascular high mortality. ...The main therapeutic target for …
In addition,a new concept has been proposed "CKD-MBD". CKD-MBD is composed of a combination of abnormal mineral …
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Navaneethan SD, et al. Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18. Am J Kidney Dis. 2009. PMID: 19692157
BACKGROUND: Phosphate binders are widely used to control serum phosphorus levels in patients with chronic kidney disease (CKD). ...SETTING & POPULATION: Patients with CKD. SELECTION CRITERIA FOR STUDIES: Randomized controlled trials. …
BACKGROUND: Phosphate binders are widely used to control serum phosphorus levels in patients with chronic kidney …
Secondary hyperparathyroidism (CKD-MBD) treatment and the risk of dementia.
Mathur A, Ahn JB, Sutton W, Chu NM, Gross AL, Segev DL, McAdams-DeMarco M. Mathur A, et al. Nephrol Dial Transplant. 2022 Oct 19;37(11):2111-2118. doi: 10.1093/ndt/gfac167. Nephrol Dial Transplant. 2022. PMID: 35512551 Free PMC article.
METHODS: Using the United States Renal Data System and Medicare claims, we identified 189 433 older adults without a diagnosis of dementia, who initiated dialysis between 2006 and 2016. SHPT treatment was defined as the use of vitamin D analogs, phosphate binders …
METHODS: Using the United States Renal Data System and Medicare claims, we identified 189 433 older adults without a diagnosis of dementia, …
333 results